Log in

OncoSec Medical Stock Price, Forecast & Analysis (NASDAQ:ONCS)

$1.93
-0.01 (-0.52 %)
(As of 11/15/2019 08:00 AM ET)
Today's Range
$1.93
Now: $1.93
$1.99
50-Day Range
$1.61
MA: $2.09
$2.40
52-Week Range
$1.60
Now: $1.93
$11.30
Volume40,000 shs
Average Volume84,268 shs
Market Capitalization$20.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.28 per share

Profitability

Net Income$-30,280,000.00

Miscellaneous

Employees33
Market Cap$20.59 million
Next Earnings Date12/13/2019 (Estimated)
OptionableNot Optionable

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.


OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

OncoSec Medical's stock reverse split before market open on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) posted its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.30) by $0.50. View OncoSec Medical's Earnings History.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release their next quarterly earnings announcement on Friday, December 13th 2019. View Earnings Estimates for OncoSec Medical.

What price target have analysts set for ONCS?

1 equities research analysts have issued 12-month price targets for OncoSec Medical's stock. Their forecasts range from $6.00 to $6.00. On average, they expect OncoSec Medical's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 210.9% from the stock's current price. View Analyst Price Targets for OncoSec Medical.

What is the consensus analysts' recommendation for OncoSec Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.

What are Wall Street analysts saying about OncoSec Medical stock?

Here are some recent quotes from research analysts about OncoSec Medical stock:
  • 1. According to Zacks Investment Research, "OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in San Diego, California. " (10/15/2019)
  • 2. Maxim Group analysts commented, "OncoSec announced a collaboration agreement with Dana-Farber Cancer Institute whereby OncoSec acquired an exclusive option to licensing rights to CAR-T candidates and associated IP from research being conducted the Marasco Laboratory." (6/28/2019)

Has OncoSec Medical been receiving favorable news coverage?

News coverage about ONCS stock has trended somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OncoSec Medical earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for OncoSec Medical.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 276,000 shares, a decline of 42.5% from the September 30th total of 480,400 shares. Based on an average daily trading volume, of 262,400 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.1% of the shares of the stock are sold short. View OncoSec Medical's Current Options Chain.

Who are some of OncoSec Medical's key competitors?

What other stocks do shareholders of OncoSec Medical own?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the folowing people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)
  • Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a number of of institutional and retail investors. Top institutional investors include D.A. Davidson & CO. (0.22%) and Salzhauer Michael (0.13%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon, Richard B Slansky and Sara Bonstein. View Institutional Ownership Trends for OncoSec Medical.

Which major investors are buying OncoSec Medical stock?

ONCS stock was acquired by a variety of institutional investors in the last quarter, including D.A. Davidson & CO. and Salzhauer Michael. Company insiders that have bought OncoSec Medical stock in the last two years include Alpha Holdings, Inc, Daniel J O'connor, James M Demesa and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $1.93.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $20.59 million. OncoSec Medical employs 33 workers across the globe.View Additional Information About OncoSec Medical.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is http://www.oncosec.com/.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]


MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  592
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel